BR112012013092A2 - ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla'' - Google Patents

''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla''

Info

Publication number
BR112012013092A2
BR112012013092A2 BR112012013092A BR112012013092A BR112012013092A2 BR 112012013092 A2 BR112012013092 A2 BR 112012013092A2 BR 112012013092 A BR112012013092 A BR 112012013092A BR 112012013092 A BR112012013092 A BR 112012013092A BR 112012013092 A2 BR112012013092 A2 BR 112012013092A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
methods
identifying whether
individual needs
related determination
Prior art date
Application number
BR112012013092A
Other languages
English (en)
Inventor
Andreas Hewelt
Carmen Infante-Duarte
Frauke Zipp
Jens Fuhrmann
Jürgen Kastler
Regina Reszka
Ulrike Rennefahrt
Original Assignee
Metanomics Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metanomics Health Gmbh filed Critical Metanomics Health Gmbh
Publication of BR112012013092A2 publication Critical patent/BR112012013092A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112012013092A 2009-12-01 2010-11-30 ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla'' BR112012013092A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09177622 2009-12-01
US29411910P 2010-01-12 2010-01-12
EP10162572 2010-05-11
US34517010P 2010-05-17 2010-05-17
PCT/EP2010/068508 WO2011067243A1 (en) 2009-12-01 2010-11-30 Means and methods for diagnosing multiple sclerosis

Publications (1)

Publication Number Publication Date
BR112012013092A2 true BR112012013092A2 (pt) 2016-10-25

Family

ID=44114626

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012013092A BR112012013092A2 (pt) 2009-12-01 2010-11-30 ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla''

Country Status (8)

Country Link
US (1) US20120238028A1 (pt)
EP (1) EP2507633A1 (pt)
JP (1) JP2013512444A (pt)
AU (1) AU2010326737A1 (pt)
BR (1) BR112012013092A2 (pt)
CA (1) CA2782415A1 (pt)
DE (1) DE112010004626T5 (pt)
WO (1) WO2011067243A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012018771A2 (pt) 2010-01-29 2017-06-20 Metanomics Gmbh ''método para dianosticar insuficência cardíaca em um sujeito''
EP3273247A1 (en) 2010-06-10 2018-01-24 Metanomics Health GmbH Methods for the diagnosis of liver diseases
GB2493142A (en) * 2011-07-20 2013-01-30 Johann Wolfgang Goethe Uni T Frankfurt Ceramide and ceramide synthase in the diagnosis and treatment of multiple sclerosis
GB201202092D0 (en) * 2012-02-07 2012-03-21 Isis Innovation Diagnosing multiple sclerosis
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
ES2552371T3 (es) * 2012-05-25 2015-11-27 Zora Biosciences Oy Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9)
DE102012209059B4 (de) * 2012-05-30 2024-05-02 Siemens Healthineers Ag Verfahren und Vorrichtung zur Bestimmung einer zeitlichen Änderung eines Biomarkers in einem Untersuchungsgebiet
JP6290398B2 (ja) * 2013-07-18 2018-03-07 ディアンティ エムエス ピーティーワイ リミテッド 多発性硬化症（ｍｓ）を監視する方法および予測キット
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
US7196323B2 (en) 2002-02-28 2007-03-27 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analyzing mixtures of substances
WO2005027733A2 (en) * 2003-09-18 2005-03-31 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing multiple sclerosis
WO2005113831A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2007050318A2 (en) * 2005-10-24 2007-05-03 Duke University Lipidomics approaches for central nervous system disorders
WO2007100782A2 (en) * 2006-02-28 2007-09-07 Metabolon, Inc. Biomarkers for amyotrophic lateral sclerosis and methods using the same
JP2009538416A (ja) * 2006-05-26 2009-11-05 フェノメノーム ディスカバリーズ インク 多発性硬化症を診断するための生物マーカー、及びその方法
US8597875B2 (en) * 2008-05-28 2013-12-03 Basf Se Method for diagnosing liver toxicity with sex specific biomarkers
WO2011127587A1 (en) * 2010-04-14 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Biomarkers for multiple sclerosis
WO2012164026A1 (en) * 2011-05-31 2012-12-06 Metanomics Health Gmbh Methods for diagnosing multiple sclerosis

Also Published As

Publication number Publication date
US20120238028A1 (en) 2012-09-20
WO2011067243A1 (en) 2011-06-09
CA2782415A1 (en) 2011-06-09
JP2013512444A (ja) 2013-04-11
DE112010004626T5 (de) 2012-10-18
AU2010326737A1 (en) 2012-06-07
EP2507633A1 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
BR112012013092A2 (pt) ''métodos de diagnóstico, método para identificar se um indivíduo necessita de uma terapia contra esclerose múltipla, métodos de determinação e previsão relacionados à esclerose múltipla''
BRPI0916015A2 (pt) "palmilha, método para fabricação de uma palmilha e calçado"
IL239277A0 (en) A method for identifying risk factors for diseases
BRPI0821804A2 (pt) Método para reconstruir uma imagem de um indivíduo
BRPI0909179A2 (pt) Composição farmacêutica, e, método de tratamento de uma doença autoimune.
EP2563930A4 (en) METHOD FOR DIAGNOSIS OF TYPE 1 DIABETES RISK AND PREVENTING TYPE 1 DIABETES
BRPI1005153A2 (pt) composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0909180A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0923624A2 (pt) palmilha, e, métodos para montar uma palmilha, e para aliviar dor de artrite
BRPI0909048A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0919937A2 (pt) composto, e, método para melhorar a atividade de adjuvante de uma imidazoquinolina
BR112012020806A2 (pt) método e aparelho para fornecer histórico de informação associado à informação de tempo
BRPI0822972A2 (pt) "método e aparelho para redução de atrito"
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0817290A2 (pt) Métodos, dispositivos, sistemas, conjuntos, e kits para retração de tecido dentro de uma cavidade oral
BRPI0912110A2 (pt) métodos para diagnosticar a toxicidade do fígado, para determinar se um composto é capaz de induzir a toxicidade no fígado em um indivíduo, e para identificar uma substância para tratar toxicidade do fígado
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
EP2363471A4 (en) IMMUNOASSAY METHOD FOR HUMAN CXCL1 PROTEIN
BRPI0920918A2 (pt) método e aparelho aprimorados para quebrar uma emulsão
BRPI0918842A2 (pt) método para tratar pacientes com esclerose múltipla com anticorpos anti-il2r
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
BRPI1014353A2 (pt) "método e dispositivo para detectar uma situação de aprisionamento"
GB0704429D0 (en) Method and apparatus for determining information concerning the identity of an individual
BR112012002001A2 (pt) método para tratar uma doença e/ou distúrbio do olho, formulação farmacêutica, e, kit
BR112012015818A2 (pt) ''método para determinação de referência de tempo de enlace descendente e terminal''

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]